DESTINY-Breast09 III期试验结果显示,相较THP方案,优赫得®联合帕妥珠单抗可将疾病进展或死亡风险降低44%,中位无进展生存期超过三年[1] 此次获批将优赫得®前移至HER2阳性转移性乳腺癌一线治疗阶段,有望改善患者的长期治疗结局 上海2026年8月12日 /美通社/ -- 阿斯利康今日宣布,由阿斯利康和第一三共共同开发与商业化的优赫得®(英文商品名:Enhertu®,通用名:...
Source LinkDESTINY-Breast09 III期试验结果显示,相较THP方案,优赫得®联合帕妥珠单抗可将疾病进展或死亡风险降低44%,中位无进展生存期超过三年[1] 此次获批将优赫得®前移至HER2阳性转移性乳腺癌一线治疗阶段,有望改善患者的长期治疗结局 上海2026年8月12日 /美通社/ -- 阿斯利康今日宣布,由阿斯利康和第一三共共同开发与商业化的优赫得®(英文商品名:Enhertu®,通用名:...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.